The drug manufacturer Morepen Laboratories said that his formulation business of 325 million rupees was pointing to ₹ 1,000 million rupees in five years, thoroughly of local and global sales.
Growth would be driven by “a deepest penetration of the market, an enlarged field force and a growing portfolio of profitable therapies and complying worldwide,” the company said. The price of its action shot in the development, ending the day more than 14 percent to ₹ 62.20, on Thursday, the EEB..
New releases
The company also said that it had launched four new products: Ticapen, Uudofix, Lycomore and Acifix, in the domestic market, in addition to Emamore last month. The new launches reflect the products led by Morepen’s research in Cardiology, Hepatology, Nutrition and Diabetology, he said.
This expansion reinforced the finished dose business (formulations) of Morepen while continued to invest in research to boost a differentiated pipe or medications, he said. The active pharmaceutical ingredients (API) used in these products are also manufactured internal in the house by Morepen in the plants approved by the USFDA, he added.
The company also said that it was a leader API exhibition for six molecules for world-lloatadine use, montelukast, downed, atorvastatin, rosuvastatin and fexofenadine. He had a presence in 82 countries, backed by an annual API manufacturing capacity of 144 metric tons, he added. His abilities integrated into the pharmaceutical value chain give him a competitive advantage in regulated and emerging markets, he said.
Posted on April 24, 2025
